Yamamoto N, Yokota K, Yamashita A, Oda M
New Drug Research Laboratories, Kanebo Ltd., Osaka, Japan.
Thromb Haemost. 1995 Jan;73(1):118-21.
Using guinea pigs, a study was conducted on the effects of KBT-3022, a new anti-platelet agent, on hemorheological properties in various tests including blood filterability, blood viscosity, shear stress-induced red blood cell (RBC) deformability and contents of ATP and 2,3-diphosphoglycerate (2,3-DPG). Oral administration of KBT-3022 at 1 and 10 mg/kg significantly increased blood filterability, and significantly reduced blood viscosity at 10 mg/kg without changing the hematocrit, plasma fibrinogen concentration or plasma viscosity. KBT-3022 (10 mg/kg, p.o.) improved RBC deformability in response to shear stress, which was evoked by passing the blood through a thin tube. This dose of KBT-3022 also increased the contents of ATP and 2,3-DPG in RBC. These findings indicate that KBT-3022 may reduce blood viscosity as a sequel to improvement of RBC deformability through direct action on RBC. The increase in the intracellular levels of ATP and 2,3-DPG was considered to be involved in this improvement of hemorheological properties. These hemorheological effects of KBT-3022 appear to be promising for the treatment of patients with ischemic vascular disease.
使用豚鼠，对新型抗血小板药物KBT - 3022在包括血液过滤性、血液粘度、剪切应力诱导的红细胞（RBC）变形性以及ATP和2,3 - 二磷酸甘油酸（2,3 - DPG）含量等各种测试中的血液流变学特性影响进行了研究。以1和10mg/kg的剂量口服KBT - 3022可显著提高血液过滤性，且在10mg/kg时可显著降低血液粘度，而血细胞比容、血浆纤维蛋白原浓度或血浆粘度均未改变。KBT - 3022（10mg/kg，口服）可改善因血液通过细管引发的剪切应力作用下的红细胞变形性。该剂量的KBT - 3022还可增加红细胞内ATP和2,3 - DPG的含量。这些发现表明，KBT - 3022可能通过直接作用于红细胞改善其变形性，进而降低血液粘度。细胞内ATP和2,3 - DPG水平的升高被认为与血液流变学特性的这种改善有关。KBT - 3022的这些血液流变学效应对于缺血性血管疾病患者的治疗似乎很有前景。
